News for 'Biocon'

Ask Ajit: 'Help! I have inherited these stocks...'

Ask Ajit: 'Help! I have inherited these stocks...'

Rediff.com23 Nov 2020

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Watch! Glimpses from DeepVeer's Bengaluru reception

Watch! Glimpses from DeepVeer's Bengaluru reception

Rediff.com22 Nov 2018

Bengaluru's celebs wish the newly-weds.

Mukesh Ambani drops out of PM's delegation to Japan

Mukesh Ambani drops out of PM's delegation to Japan

Rediff.com31 Aug 2014

R C Bhargava, Kiran Mazumdar-Shaw & Dinesh K Sarraf are other members of the business delegation

India's biotech export touches $1.2 billion

India's biotech export touches $1.2 billion

Rediff.com18 Jun 2007

India's export revenue from biotechnology grew by 47 per cent to reach to 1.2 billion dollars in the financial year ended March 2007, a survey said.

For 8th year running, Mukesh Ambani is richest Indian

For 8th year running, Mukesh Ambani is richest Indian

Rediff.com25 Sep 2019

Others in the top 10 include Uday Kotak at the 6th place with a wealth of Rs 94,100 crore, Cyrus S Poonawalla at 7th position with Rs 88,800 crore assets, Cyrus Pallonji Mistry at 8th spot with a wealth of Rs 76,800 crore, Shapoor Pallonji at 9th position with a net worth of Rs 76,800 crore and Dilip Shanghvi at 10th slot with Rs 71,500-crore wealth.

Nokia, Wipro, H-P get nod for SEZ

Nokia, Wipro, H-P get nod for SEZ

Rediff.com21 Dec 2005

The government on Wednesday granted approval to Nokia, Wipro, Hewlett Packard, Reliance, Biocon, Ranbaxy Laboratories, Mahindra and Mahindra, Reliance energy and Adani Group's to set up Special Economic zones.

Sitharaman, Mazumdar-Shaw's exchange livens Twitter

Sitharaman, Mazumdar-Shaw's exchange livens Twitter

Rediff.com19 Sep 2019

Sitharaman, who is not known to reply to comments made on her Twitter handle, instantly choose to respond to drug-maker Biocon chairman Kiran Mazumdar-Shaw's criticism of lack of fiscal measures to support growth.

Biotech boom -- but where are the jobs?

Biotech boom -- but where are the jobs?

Rediff.com17 May 2007

Today, an engineer from an average college can easily land an IT job. What about the biotech graduate, asks Rashmi Bansal?

Drug firms bet big on SEZs

Drug firms bet big on SEZs

Rediff.com12 Apr 2006

Small players make it big with off-patent drugs

Small players make it big with off-patent drugs

Rediff.com30 Apr 2007

Competing with established biotech companies in India such as Wockhardt, Biocon and Reliance Life Sciences, small biotech companies such as Zenotech, BV Biocorp and Intas Biopharma are likely to emerge as major players in biogeneric drugs.

Innovate and create wealth

Innovate and create wealth

Rediff.com1 Apr 2006

Researchers and scientists in India would have to be innovative if the country wished to unleash its vast intellectual potential, chairman and managing director of Biocon Ltd Kiran Mazumdar Shaw said on Saturday.

Indian pharma exports report double-digit growth after 3 yrs

Indian pharma exports report double-digit growth after 3 yrs

Rediff.com3 May 2019

The only category of pharmaceuticals that showed a negative growth in exports this time was herbal products, exports of which stood at $299 million as compared to $ 312 million in the previous year.

Do not fear failure: Shaw

Do not fear failure: Shaw

Rediff.com13 Feb 2008

Addressing aspiring entrepreneurs, Biocon Chief Shaw adviced them never to fear failure.

India Inc hails Jaitley's reform measures

India Inc hails Jaitley's reform measures

Rediff.com24 Aug 2019

Bharti Airtel Chairman Sunil Bharti Mittal said India has lost one of the finest political leaders and a legal luminary.

M&M replaces Hero Honda in Sensex

M&M replaces Hero Honda in Sensex

Rediff.com26 May 2007

Utility vehicles manufacturer Mahindra & Mahindra will replace Hero Honda in the country's benchmark index Sensex from July 9.

Stocks to create long-term wealth

Stocks to create long-term wealth

Rediff.com25 Sep 2020

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

3 Indians in Fortune's bizwomen list

3 Indians in Fortune's bizwomen list

Rediff.com11 Nov 2005

Kiran Mazumdar-Shaw, chairman and managing director of Biocon, Chanda Kochar, executive director of ICICI Bank and Vidya Chhabria, chairman of Jumbo Group

The 2 BIG challenges facing India Inc

The 2 BIG challenges facing India Inc

Rediff.com16 Jul 2020

As Covid-19 cases surge in India, companies have realised it's a tightrope walk between maintaining production and ensuring employee safety.

Govt approves RIL, Wipro SEZs

Govt approves RIL, Wipro SEZs

Rediff.com5 Sep 2005

The government on Monday approved the proposals of Reliance Industries, Wipro, Hewlett Packard and Biocon to set up Special Economic Zones -- a move that is expected to generate at least 67,000 jobs by March 2006.

Chanda Kochhar, Kidwai in <i>Fortune</i>'s list

Chanda Kochhar, Kidwai in Fortune's list

Rediff.com11 Oct 2006

Three Indian women -- ICICI Bank deputy managing director Chanda Kochhar, HSBC India CEO Naina Lal Kidwai and Biocon head Kiran Mazumdar-Shaw -- have been named among the world's 50 most powerful businesswomen by the Fortune magazine.

Sensex soars 237 points ahead of Brexit poll outcome

Sensex soars 237 points ahead of Brexit poll outcome

Rediff.com23 Jun 2016

Participants will watch out for the Brexit poll outcome in the late morning trades tomorrow.

First-time investor: 'I can afford only low-price stocks'

First-time investor: 'I can afford only low-price stocks'

Rediff.com12 Jan 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your queries.

Mumbai hospitals await FDA guidance on Ranbaxy drugs

Mumbai hospitals await FDA guidance on Ranbaxy drugs

Rediff.com10 Jun 2013

Earlier, Jaslok Hospital had issued an advisory to its doctors to avoid prescribing drugs manufactured by Ranbaxy.

Making losses in stocks? Here's help

Making losses in stocks? Here's help

Rediff.com21 Sep 2020

Ajit Mishra, vice president, Research, Religare Broking, answers your queries

Syngene to enter drug discovery

Syngene to enter drug discovery

Rediff.com24 May 2004

ASK AJIT: 'Accumulate', 'Hold' Or 'Exit'?

ASK AJIT: 'Accumulate', 'Hold' Or 'Exit'?

Rediff.com11 May 2021

Ajit Mishra, vice president, Research, Religare Broking, answers your queries

12 new Indian scrips in MSCI

12 new Indian scrips in MSCI

Rediff.com14 May 2005

'Red tape stifling India's biotech sector'

'Red tape stifling India's biotech sector'

Rediff.com15 Apr 2003

Bureaucratic delays are stifling growth in the sector. India should be far more aggressive in launching 'look alike' biological molecules in a fast track manner.

Nifty holds 8,500 amid choppy trades; Broader markets outshine

Nifty holds 8,500 amid choppy trades; Broader markets outshine

Rediff.com22 Jul 2016

The BSE Mid-Cap index was currently up 0.83%. The BSE Small-Cap index was currently up 0.8%.

Ranbaxy tops in patents filing in developing world

Ranbaxy tops in patents filing in developing world

Rediff.com17 Mar 2003

Domestic pharma giant Ranbaxy Laboratories Limited has topped the list of patent filers in the area of drug applications from the Third World countries last year with 64 new formulations.\n\n\n\n

The story of India's richest woman!

The story of India's richest woman!

Rediff.com22 Feb 2005

Mukesh Ambani is the world's 10th richest man!

Mukesh Ambani is the world's 10th richest man!

Rediff.com27 Feb 2019

Jeff Bezos of Amazon tops the list for the second consecutive year with networth of $147 billion.

How to apply for an IPO

How to apply for an IPO

Rediff.com6 Mar 2004

IT industry is largest creator of jobs: Murthy

IT industry is largest creator of jobs: Murthy

Rediff.com26 Nov 2014

Narayan Murthy says the software industry has boosted the international image of India like no other sector.

Plasma therapy isn't proven treatment for COVID-19: Govt

Plasma therapy isn't proven treatment for COVID-19: Govt

Rediff.com29 Apr 2020

Addressing a press briefing, health ministry Joint Secretary Lav Agarwal said currently there are no approved therapies for COVID-19 and there is not enough evidence to claim that plasma therapy can be used for treatment of the disease.